DUBLIN, Feb. 14, 2024 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will
report its 2023 full year and fourth quarter financial results on
Wednesday, February 28, 2024, after
the close of the U.S. financial markets. Company management will
host a live audio webcast at 4:30 p.m.
ET / 9:30 p.m. GMT to discuss
2023 full year and fourth quarter financial results and provide a
business and financial update.
Audio webcast/conference call:
U.S. Dial-In
Number: +1 888 350 4423
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 6907242
Interested parties may access the live audio webcast via the
Investors section of the Jazz Pharmaceuticals website at
https://investor.jazzpharma.com/investors/events-presentations. To
ensure a timely connection, it is recommended that participants
register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors
section of the Jazz Pharmaceuticals website at
https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose
is to innovate to transform the lives of patients and their
families. We are dedicated to developing life-changing medicines
for people with serious diseases – often with limited or no
therapeutic options. We have a diverse portfolio of marketed
medicines and novel product candidates, from early- to late-stage
development, in neuroscience and oncology. Within these therapeutic
areas, we are identifying new options for patients by actively
exploring small molecules and biologics, and through innovative
delivery technologies and cannabinoid science. Jazz is
headquartered in Dublin, Ireland and has employees around
the globe, serving patients in nearly 75 countries. Please
visit www.jazzpharmaceuticals.com for more information.
Investors:
Andrea N.
Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media Contact:
Kristin
Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Logo
- https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-report-2023-full-year-and-fourth-quarter-financial-results-on-february-28-2024-302062153.html